PRA Recognized for Quality with Multiple CRO Leadership Awards

RALEIGH, N.C., March 6, 2014 /PRNewswire/ -- PRA, a leading clinical research organization, today announced it has won two CRO Leadership Awards for quality. For its full-service offering, PRA received the "Quality in Emerging Biotech" award, while its Embedded services division, RPS Strategic Solutions, received the "Overall Quality" award. Organized by Life Science Leader Magazine, the annual competition recognizes CROs for outstanding strides in key areas of trial delivery. 

"PRA is pleased to receive the awards because quality is the single most important element at PRA. It is deeply ingrained in every PRA process and system. We drive quality throughout the company and continuously challenge ourselves to improve and innovate," said Colin Shannon, president and CEO, PRA. "PRA is dedicated to working in close partnerships with emerging biotech companies to successfully bring powerful new life-saving medicines to patients who need them."

"We are honored to be recognized as a leader in providing the highest quality services in support of our partners' product development portfolio," said Harris Koffer, president, RPS Strategic Solutions division. "Our talented team of highly experienced professionals have a passion for customer service and quality, and an unwavering commitment to helping our partners bring innovative, life-changing therapeutics to patients in need."

The quality recognition follows recent accolades for PRA, including PharmaTimes Magazine's "International Clinical Company of the Year" for 2014 and "Clinical Company of the Year" for 2012 and 2013.  

About PRA
One of the world's largest CROs, PRA is transforming clinical trials through our people, innovation and operational transparency. Our 10,000+ employees operate in more than 80 countries, delivering a broad spectrum of full-service and Embedded clinical trial solutions that meet the demands of a diverse marketplace.

Over the last 30+ years, PRA has established a reputation for specialized expertise and success in a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. Our forward-thinking approach to clinical research innovation, customized recruitment strategies and technological advances continues to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email [email protected].

SOURCE PRA